494 results on '"Chabre, Olivier"'
Search Results
2. Position statement on the diagnosis and management of acromegaly: The French National Diagnosis and Treatment Protocol (NDTP)
3. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study
4. Factitious, or iatrogenic but unexpected Cushing's syndrome
5. Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome
6. Adolescent‐ and adult‐onset neuroblastic tumor: A retrospective multicenter observational study of patients diagnosed in France between 2000 and 2020
7. Prevalence and treatment of osteoporosis and bone fractures in Cushing's syndrome across Europe
8. Lessons from prospective longitudinal follow-up of a French APECED cohort
9. Adherence to growth hormone therapy guidelines in a real-world French cohort of adult patients with growth hormone deficiency
10. Pneumocystis pneumonia can complicate medical treatment of hypercortisolism even in outpatients with Cushing's disease
11. Response to “Letter to the Editor from Piazzola and Castinetti: ‘DISCONTINUATION OF DRUG TREATMENT IN CUSHING’S DISEASE NOT CURED BY PITUITARY SURGERY”
12. Unilateral adrenalectomy in primary bilateral macronodular hyperplasia
13. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study
14. Bilateral adrenalectomy in Cushing's disease: Altered long-term quality of life compared to other treatment options
15. Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial.
16. Discontinuation of Drug Treatment in Cushing's Disease Not Cured by Pituitary Surgery.
17. EPAS1‐mutated paragangliomas associated with haemoglobin disorders.
18. Discontinuation of drug treatment in Cushing’s disease not cured by pituitary surgery
19. THU033 High Prevalence Of Venous Thrombotic Events In Cushing’s Syndrome: Data From ERCUSYN
20. Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions
21. The difficulties of pseudo-Cushing's syndrome (or “non-neoplastic hypercortisolism”)
22. SFE/SFEDP adrenal insufficiency French consensus: Introduction and handbook
23. Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation
24. Group 2: Adrenal insufficiency: screening methods and confirmation of diagnosis
25. Group 1. Epidemiology of primary and secondary adrenal insufficiency: Prevalence and incidence, acute adrenal insufficiency, long-term morbidity and mortality
26. High prevalence of venous thrombotic events in Cushing's syndrome: data from ERCUSYN and details in relation to surgery.
27. Venous thrombotic events (VTE) across ERCUSYN: details of these VTE's and do centres anticoagulate on a routine bases?
28. Aberrant activation of Wnt/[beta]-Catenin signaling pathway drives the expression of poor prognosis-associated microRNAs in adrenocortical cancer
29. Pro: Should patients with adrenal incidentaloma and autonomous cortisol secretion be treated with surgery?
30. Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the Cranioexe randomized placebo-controlled trial
31. SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook
32. Aberrant activation of Wnt/β-Catenin signaling pathway drives the expression of poor prognosis-associated microRNAs in adrenocortical cancer with a major impact on miR-139-5p and its host gene PDE2A
33. Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France
34. Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN
35. Management of a Composite Pheochromocytoma (Pheochromocytoma/Neuroblastoma) in Adult Patient Recurring After Several Years: A Complex Case Report
36. Prognostic Impact of Paraneoplastic Cushing’s Syndrome in Small-Cell Lung Cancer
37. Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d’Etude des Tumeurs Endocrines
38. Management of a Composite Pheochromocytoma (Pheochromocytoma/Neuroblastoma) in Adult Patient Recurring After Several Years: A Complex Case Report.
39. Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France.
40. Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence
41. Treatment of cushing's disease (CD) after primary failure of pituitary surgery or recurrence: evaluation of long-term control by medical treatment
42. Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN.
43. Pituitary MRI features in acromegaly resulting from ectopic GHRH secretion from a neuroendocrine tumor: analysis of 30 cases
44. Clinical practice outcomes from 107 patients with Cushing's syndrome treated with osilodrostat in France
45. Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases
46. An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion
47. Rise and fall of thyroid radiologic density during the time course of amiodarone-induced thyrotoxicosis
48. Efficacy and tolerance of osilodrostat in patients with Cushing’s syndrome due to adrenocortical carcinomas
49. Is Adrenal Venous Sampling Mandatory before Surgical Decision in Case of Primary Hyperaldosteronism?
50. Prolonged and Severe Gestational Thyrotoxicosis Due to Enhanced hCG Sensitivity of a Mutant Thyrotropin Receptor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.